The tumor-suppressive long noncoding RNA DRAIC inhibits protein translation and induces autophagy by activating AMPK

Area of Science:

• Molecular Biology
• Oncology
• Genetics

Background:

• Long noncoding RNAs (lncRNAs) are crucial regulators of cellular processes.
• DRAIC, a specific lncRNA, is downregulated in advanced prostate cancer and linked to poor patient outcomes in various cancers.
• The NF-κB pathway is frequently dysregulated in cancer.

Purpose of the Study:

• To investigate the role of DRAIC in glioblastoma.
• To elucidate the molecular mechanisms by which DRAIC exerts its effects.
• To explore the therapeutic potential of DRAIC in cancer treatment.

Main Methods:

• Cell line studies using glioblastoma-derived cells.
• Analysis of gene expression and protein levels.
• Investigation of signaling pathways including NF-κB, AMPK, and mTOR.
• Xenograft models to assess tumor growth in vivo.

Main Results:

• DRAIC suppresses glioblastoma cell invasion, migration, colony formation, and xenograft growth.
• DRAIC activates AMP-activated protein kinase (AMPK) by downregulating GLUT1, a target of NF-κB.
• Activation of AMPK by DRAIC leads to mTOR repression, decreased protein translation, and increased autophagy.
• DRAIC impacts both the NF-κB and AMPK-mTOR pathways.

Conclusions:

• DRAIC functions as a tumor suppressor in glioblastoma and potentially other cancers.
• DRAIC's multifaceted regulation of key oncogenic pathways underscores its significance.
• lncRNAs like DRAIC represent promising targets for cancer therapy.